Novartis Institute for Tropical Diseases Pte Ltd, 10 Biopolis Road #05-01, Chromos, 138670, Singapore.
Pharmaceuticals (Basel). 2012 Nov 9;5(11):1210-35. doi: 10.3390/ph5111210.
In the fight against tuberculosis, cell wall permeation of chemotherapeutic agents remains a critical but largely unsolved question. Here we review the major mechanisms of small molecule penetration into and efflux from Mycobacterium tuberculosis and other mycobacteria, and outline how these mechanisms may contribute to the development of phenotypic drug tolerance and induction of drug resistance. M. tuberculosis is intrinsically recalcitrant to small molecule permeation thanks to its thick lipid-rich cell wall. Passive diffusion appears to account for only a fraction of total drug permeation. As in other bacterial species, influx of hydrophilic compounds is facilitated by water-filled open channels, or porins, spanning the cell wall. However, the diversity and density of M. tuberculosis porins appears lower than in enterobacteria. Besides, physiological adaptations brought about by unfavorable conditions are thought to reduce the efficacy of porins. While intracellular accumulation of selected drug classes supports the existence of hypothesized active drug influx transporters, efflux pumps contribute to the drug resistant phenotype through their natural abundance and diversity, as well as their highly inducible expression. Modulation of efflux transporter expression has been observed in phagocytosed, non-replicating persistent and multi-drug resistant bacilli. Altogether, M. tuberculosis has evolved both intrinsic properties and acquired mechanisms to increase its level of tolerance towards xenobiotic substances, by preventing or minimizing their entry. Understanding these adaptation mechanisms is critical to counteract the natural mechanisms of defense against toxic compounds and develop new classes of chemotherapeutic agents that positively exploit the influx and efflux pathways of mycobacteria.
在与结核病的斗争中,化疗药物的细胞穿透仍然是一个关键但在很大程度上尚未解决的问题。在这里,我们回顾了小分子穿透和流出结核分枝杆菌和其他分枝杆菌的主要机制,并概述了这些机制如何导致表型药物耐受性的发展和药物耐药性的诱导。由于其厚厚的富含脂质的细胞壁,结核分枝杆菌本身对小分子的穿透具有很强的抵抗力。被动扩散似乎只占总药物渗透的一小部分。与其他细菌物种一样,亲水性化合物的流入是由充满水的开放通道或跨壁孔(porin)来促进的。然而,结核分枝杆菌的孔蛋白的多样性和密度似乎低于肠杆菌。此外,不利条件带来的生理适应被认为降低了孔蛋白的效率。虽然某些药物类别的细胞内积累支持了假设的主动药物流入转运蛋白的存在,但外排泵通过其天然丰度和多样性以及高度诱导的表达,导致了药物耐药表型。在吞噬的、非复制的持续存在和多药耐药菌中观察到外排转运蛋白表达的调节。总的来说,结核分枝杆菌通过阻止或最小化外来物质的进入,进化出了内在特性和获得性机制,来提高其对外来物质的耐受性。了解这些适应机制对于对抗有毒化合物的天然防御机制和开发新的抗结核分枝杆菌药物类别的积极利用流入和流出途径至关重要。